Genelux CORP Form 4 insider transactions

A Genelux Corp executive, Ralph Smalling, acquired shares and stock options, according to a recent SEC filing.

Genelux Corp's General Counsel, Sean Ryder, acquired 22,000 shares of common stock and 30,000 stock options on December 18, 2024.

A Genelux Corp executive, Yong Yu, acquired 29,000 shares of common stock and 39,000 stock options on December 18, 2024.

Joseph Cappello, VP of Pharmaceutical Development at Genelux Corp, acquired 29,000 shares of common stock and 39,000 stock options on December 18, 2024.

Genelux Corp's Chief Financial Officer, Lourie S. Zak, acquired 41,650 shares of common stock and 56,525 stock options on December 18, 2024.

Genelux Corp's CEO, Thomas Zindrick, acquired 134,500 restricted stock units and 183,000 stock options on December 18, 2024.

Genelux Corporation's CEO, Thomas Zindrick, sold 14,315 shares of common stock on December 16, 2024, to cover estimated taxes related to the vesting of restricted stock units.

Genelux Corporation's CFO, Lourie S. Zak, sold 2,103 shares of common stock on December 16, 2024, to cover estimated taxes related to vesting restricted stock units.

Ralph Smalling, Head of Regulatory at Genelux Corp, sold 2,510 shares of common stock on December 16, 2024, to cover estimated taxes related to vesting restricted stock units.

Joseph Cappello, VP of Pharmaceutical Development at Genelux Corp, sold 6,300 shares of common stock on December 16, 2024, to cover estimated taxes related to vesting restricted stock units.

Paul Scigalla, Chief Medical Officer of Genelux Corp, reports the acquisition of stock options.

James L. Tyree, a director of Genelux Corp, filed an amended Form 4 to correct a previous report that mistakenly indicated a sale of 1,730 shares of common stock that did not occur.

Director Aladar Szalay of Genelux Corp sold shares of common stock in multiple transactions on September 12 and 13, 2024.

Director James L. Tyree of Genelux Corp sold 1,730 shares of common stock at an average price of $2.6005, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Director Aladar Szalay reports selling shares of Genelux Corp in a series of transactions between September 9th and September 11th, 2024.

Director Aladar Szalay of Genelux Corp sold 42,818 shares of common stock at an average price of $2.0929 on September 3, 2024.

Director Aladar Szalay reported selling shares of Genelux Corp in a series of transactions between August 28 and August 30, 2024.

Director Aladar Szalay reported selling shares of Genelux Corp in multiple transactions during August 2024.

Director James L Tyree reports acquisition of restricted stock units and stock options in Genelux Corp.

Director Mary Mirabelli reported the acquisition of restricted stock units and stock options in Genelux Corp on August 1, 2024.

Director Thomas John reports acquiring and disposing of Genelux Corp shares and stock options in a recent filing.

Director John W. Smither reports acquiring and disposing of Genelux Corp shares, including restricted stock units and stock options.

Genelux Corp CEO Thomas Zindrick reports the acquisition of common stock through restricted stock units and the Employee Stock Purchase Plan, increasing his beneficial ownership.

Lourie S. Zak, CFO of Genelux Corporation, reports the acquisition of common stock and restricted stock units (RSUs) in recent transactions.

Ralph Smalling, Head of Regulatory at Genelux Corp, reports acquiring common stock and restricted stock units.

Joseph Cappello, VP of Pharmaceutical Development at Genelux Corp, reports acquiring common stock through restricted stock units (RSUs) that vested in February and March 2024.

VP of Clinical Trial Operations at Genelux Corp, Yu Yong, reports acquisition and disposal of common stock and restricted stock units.

Sean Ryder, General Counsel of Genelux Corp, reports acquisition and disposal of company stock, including transactions related to vested restricted stock units and employee stock purchase plan.

Caroline Jewett, Head of Quality at Genelux Corp, reports acquisition and disposal of common stock, including sales to cover taxes related to vested restricted stock units.

Director Tyree James L reports purchase and sale of Genelux Corp common stock and warrants, including a transaction matchable under Section 16(b) of the Securities Exchange Act.